The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kurenkov A.L.

National Medical Research Center for Children’s Health

Kuzenkova L.M.

National Medical Research Center for Children’s Health

Bursagova B.I.

National Medical Research Center for Children’s Health

Klochkova O.A.

National Medical Research Center for Children’s Health

Chernikov V.V.

National Medical Research Center for Children’s Health

Kuznetsova M.A.

National Medical Research Center for Children’s Health

Ashrafova U.S.

National Medical Research Center for Children’s Health

Kuprianova O.S.

National Medical Research Center for Children’s Health

Botulinum toxin type A (Incobotulinum toxin A) in spastic forms of cerebral palsy: a retrospective analysis of clinical experience

Authors:

Kurenkov A.L., Kuzenkova L.M., Bursagova B.I., Klochkova O.A., Chernikov V.V., Kuznetsova M.A., Ashrafova U.S., Kuprianova O.S.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(7): 68‑77

DOI: 10.17116/jnevro202012007168

Views: 1876

Downloaded: 53

Download PDF (RU)
Contact the author
Table of contents

BOTULINUM TOXIN TYPE A (INCOBOTULINUM TOXIN A) IN SPASTIC FORMS OF CEREBRAL PALSY: A RETROSPECTIVE ANALYSIS OF CLINICAL EXPERIENCE
BOTULINUM TOXIN TYPE A (INCOBOTULINUM TOXIN A) IN SPASTIC FORMS OF CEREBRAL PALSY: A RETROSPECTIVE ANALYSIS OF CLINICAL EXPERIENCE

To cite this article:

Kurenkov AL, Kuzenkova LM, Bursagova BI, et al. . Botulinum toxin type A (Incobotulinum toxin A) in spastic forms of cerebral palsy: a retrospective analysis of clinical experience. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(7):68‑77. (In Russ.)
https://doi.org/10.17116/jnevro202012007168

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Safety and effi­cacy of Rela­tox in comparison with Dysport in the treatment of focal spasticity of the upper limb in patients after stroke and traumatic brain injury (results of a prospective simple blind randomized comparative study in para­llel groups). S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):79-85
Abobotulinumtoxin A inje­ctions for the chro­nic sialorrhea correction in children: Russian retrospective multicenter study. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):53-61
Aica­rdi—Goutieres syndrome type 6 asso­ciated with a compound hete­rozygous variant in ADAR: a first case report in the Russian popu­lation. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):131-138
Sequential use of botu­linum toxin A and bovhyaluronidase azoximer in the correction of post-stroke spasticity. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):80-85
Intrathecal baclofen therapy: a 30-year expe­rience. Burdenko's Journal of Neurosurgery. 2024;(3):96-102
Five-year follow-up after neurosurgery complicated by facial neuropathy. Burdenko's Journal of Neurosurgery. 2024;(4):50-55
Capsular contracture after reco­nstructive plastic surgery for breast cancer. P.A. Herzen Journal of Onco­logy. 2024;(6):78-83
Sele­ctive dorsal rhizotomy in children with here­ditary spastic para­plegia. Burdenko's Journal of Neurosurgery. 2025;(1):46-51
Prevention of pathological skin scars (experimental study). Plastic Surgery and Aesthetic Medi­cine. 2025;(1):32-38

OBJECTIVE

A retrospective analysis of the experience of using Incobotulinum toxin A injections for the treatment of spasticity in children with cerebral palsy (CP).

MATERIAL AND METHODS

One hundred and eighty-five children with spastic forms of CP, including 114 boys (61,6%), were studied. The average age of the patients was 3,8±2,5 years; the average weight was 14,2±6,9. The patients received injections of Incobotulinum toxin A according to registered indications or recommendations of a consultation of specialists and voluntary informed consent of the patient’s representative. At least 1 point decrease of muscle tone according to the modified Ashworth scale was used as a criterion of the antispastic effect of Incobotulinum toxin A.

RESULTS

The total dose of Incobotulinum toxin A for the whole group of patients with CP was 154,5±67,7 U and 11,6±4,7 U per kg/body weight. The gracilis muscle (65,4% of cases, 95%CI 58,1—72,2) and the gastrocnemius muscle (49,4% of cases, 95%CI 41,8—56,6) were the most frequently injected targets in the lower extremities, and the pronator teres muscle (58,9% of cases, 95%CI 51,5—66,1) — in the upper extremities. Adverse events were observed in 13 patients (7,0%). They were mild in 9 patients and moderate in 4 patients.

CONCLUSION

Our data confirmed the effectiveness and safety of Incobotulinum toxin A injections in spastic CP. The calculated average doses of Incobotulinum toxin A for target muscles and the frequency of different spasticity patterns could serve as a reference for the botulinum therapy planning.

Keywords:

cerebral palsy
botulinum toxin type A
Incobotulinum toxin A
modified Ashworth scale
spasticity

Authors:

Kurenkov A.L.

National Medical Research Center for Children’s Health

Kuzenkova L.M.

National Medical Research Center for Children’s Health

Bursagova B.I.

National Medical Research Center for Children’s Health

Klochkova O.A.

National Medical Research Center for Children’s Health

Chernikov V.V.

National Medical Research Center for Children’s Health

Kuznetsova M.A.

National Medical Research Center for Children’s Health

Ashrafova U.S.

National Medical Research Center for Children’s Health

Kuprianova O.S.

National Medical Research Center for Children’s Health

Received:

18.05.2020

Accepted:

20.05.2020

List of references:

  1. Koman LA, Mooney JF 3rd, Smith B, Goodman A, Mulvaney T. Management of cerebral palsy with botulinum-a toxin: Preliminary investigation. J. Pediatr. Orthop. 1993;13:489-495. 
  2. Strobl W, Theologis T, Brunner R, Kocer S, Viehweger E, Pascual-Pascual I, Placzek R. Best clinical practice in botulinum toxin treatment for children with cerebral palsy. Toxins (Basel). 2015;7(5):1629-1648. https://doi.org/10.3390/toxins7051629
  3. Multani I, Manji J, Hastings-Ison T, Khot A, Graham K. Botulinum toxin in the management of children with cerebral palsy. Paediatr Drugs. 2019;21(4):261-281.  https://doi.org/10.1007/s40272-019-00344-8
  4. Koman LA, Mooney JF 3rd, Smith BP, Goodman A, Mulvaney T. Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial. J. Pediatr. Orthop. 1994;14(3):299-303. 
  5. Sutherland DH, Kaufman KR, Wyatt MP, Chambers HG, Mubarak SJ. Double-blind study of botulinum toxin A toxin injections into the gastrocnemius muscle in patients with cerebral palsy. Gait Posture. 1999;10(1):1-9. 
  6. Koman LA, Brashear A, Rosenfeld S, Chambers H, Russman B, Rang M, Root L, Ferrari E, Garcia de Yebenes Prous J, Smith BP, Turkel C, Walcott JM, Molloy PT. Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics. 2001;108(5):1062-1071.
  7. Baker R, Jasinski M, Maciag-Tymecka I, Michalowska-Mrozek J, Bonikowski M, Carr L, MacLean J, Lin JP, Lynch B, Theologis T, Wendorff J, Eunson P, Cosgrove A. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study. Dev. Med. Child Neurol. 2002;44(10):666-675. 
  8. Polak F, Morton R, Ward C, Wallace WA, Doderlein L, Siebel A. Double-blind comparison of two doses of botulinum toxin A injected into calf muscle in children with hemiplegic cerebral palsy. Dev Med Child Neurol. 2002;44:551-555. 
  9. Graham HK, Aoki KR, Autti-Rämö I, Boyd RN, Delgado MR, Gaebler-Spira DJ, Gormley ME, Guyer BM, Heinen F, Holton AF, Matthews D, Molenaers G, Motta F, García Ruiz PJ, Wissel J. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture. 2000;11(1):67-79. Review.
  10. Koman LA, Paterson Smith B, Balkrishnan R. Spasticity associated with cerebral palsy in children: guidelines for the use of botulinum A toxin. Paediatr. Drugs. 2003;5(1):11-23. Review.
  11. Mall V, Heinen F, Siebel A, Bertram C, Hafkemeyer U, Wissel J, Berweck S, Haverkamp F, Nass G, Döderlein L, Breitbach-Faller N, Schulte-Mattler W, Korinthenberg R. Treatment of adductor spasticity with BTX-A in children with CP: a randomized, double-blind, placebo-controlled study. Dev. Med. Child Neurol. 2006;48(1):10-13.  https://doi.org/10.1017/S0012162206000041
  12. Heinen F, Desloovere K, Schroeder AS, Berweck S, Borggraefe I, van Campenhout A, Andersen GL, Aydin R, Becher JG, Bernert G, Caballero IM, Carr L, Valayer EC, Desiato MT, Fairhurst C, Filipetti P, Hassink RI, Hustedt U, Jozwiak M, Kocer SI, Kolanowski E, Krägeloh-Mann I, Kutlay S, Mäenpää H, Mall V, McArthur P, Morel E, Papavassiliou A, Pascual-Pascual I, Pedersen SA, Plasschaert FS, van der Ploeg I, Remy-Neris O, Renders A, Di Rosa G, Steinlin M, Tedroff K, Valls JV, Viehweger E, Molenaers G. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur. J. Paediatr. Neurol. 2010;14:45-66.  https://doi.org/10.1016/j.ejpn.2009.09.005
  13. Love SC, Novak I, Kentish M, Desloovere K, Heinen F, Molenaers G, O’Flaherty S, Graham HK; Cerebral Palsy Institute. Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement. Eur. J. Neurol. 2010;17 Suppl 2:9-37.  https://doi.org/10.1111/j.1468-1331.2010.03126.x
  14. Fehlings D, Novak I, Berweck S, Hoare B, Stott NS, Russo RN. Botulinum toxin assessment, intervention and follow-up for paediatric upper limb hypertonicity: international consensus statement. European Journal of Neurology. 2010;17(Suppl. 2):38-56.  https://doi.org/10.1111/j.1468-1331.2010.03127.x
  15. Delgado MR, Hirtz D, Aisen M, Ashwal S, Fehlings DL, McLaughlin J, Morrison LA, Shrader MW, Tilton A, Vargus-Adams J. Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2010;74(4):336-343.  https://doi.org/10.1212/WNL.0b013e3181cbcd2f
  16. Delgado MR, Bonikowski M, Carranza J, Dabrowski E, Matthews D, Russman B, Tilton A, Velez JC, Grandoulier AS, Picaut P. Safety and efficacy of repeat open-label AbobotulinumtoxinA treatment in pediatric cerebral palsy. J. Child Neurol. 2017;32(13):1058-1064. https://doi.org/10.1177/0883073817729918
  17. Tilton A, Russman B, Aydin R, Dincer U, Escobar RG, Kutlay S, Lipczyk Z, Velez JC, Grandoulier AS, Tse A, Picaut P, Delgado MR. AbobotulinumtoxinA (Dysport®) improves function according to goal attainment in children with dynamic equinus due to cerebral palsy. J. Child Neurol. 2017;32(5):482-487.  https://doi.org/10.1177/0883073816686910
  18. Novak I, Morgan C, Fahey M, Finch-Edmondson M, Galea C, Hines A, Langdon K, Namara MM, Paton MC, Popat H, Shore B, Khamis A, Stanton E, Finemore OP, Tricks A, Te Velde A, Dark L, Morton N, Badawi N. State of the Evidence Traffic Lights 2019: Systematic Review of Interventions for Preventing and Treating Children with Cerebral Palsy. Curr Neurol Neurosci Rep. 2020;20(2):3.  https://doi.org/10.1007/s11910-020-1022-z
  19. Leon-Valenzuela A, Sanchez Palacios J, del Pino Algarrada R. Clinical practice with incobotulinumtoxina (Xeomin) in the treatment of spasticity in children with cerebral palsy. Toxicon. 2016;123:S53. 
  20. Hijazi S, Arcas M. Effectiveness and safety assessment of incobotulinumtoxina (Xeomin) injections in the lower-limb muscles of young, low-weight children with cerebral palsy. Toxicon. 2016;123:S39. 
  21. NeuroKids: child neurology workbook (Ed. Prof. F. Heinen). Kohlhammer, 2017.
  22. Heinen F, Kanovský P, Schroeder SA, Berweck S, Chambers HG, Dabrowski E, Geister TL, Dersch H, Martinez-Torres FJ, Lehn A, Pulte I, Gaebler-Spira D. Efficacy and safety of IncobotulinumtoxinA for lower-limb spasticity in children and adolescents with cerebral palsy. Toxicon. 2018;156:S44. 
  23. Kanovský P, Heinen F, Schroeder SA, Berweck S, Chambers HG, Dabrowski E, Geister TL, Dersch H, Martinez-Torres FJ, Lehn A, Pulte I, Martinez-Torres FJ, Gaebler-Spira D. Long-term safety and efficacy of IncobotulinumtoxinA for lower- or combined upper- and lower-limb spasticity in children and adolescents with cerebral palsy. Toxicon. 2018;156:S56. 
  24. Thomason P, Rodda J, Willoughby K, Graham K. Orthopaedic assessment. In book: Cerebral palsy: science and clinical practice (Eds. B. Dan, M. Mayston, N. Paneth, L. Rosenbloom). London: Mac Keith Press, 2014;287-311. 
  25. Franzen M, Hägglund G, Alriksson-Schmidt A. Treatment with botulinum toxin A in a total population of children with cerebral palsy — a retrospective cohort registry study. BMC Musculoskelet. Disord. 2017;18(1):520.  https://doi.org/10.1186/s12891-017-1880-y
  26. Hägglund G, Wagner P. Development of spasticity with age in a total population of children with cerebral palsy. BMC Musculoskelet Disord. 2008;9:150.  https://doi.org/10.1186/1471-2474-9-150
  27. Eliasson AC, Burtner P. Improving Hand Function in Children with Cerebral Palsy. London: Mac Keith Press, 2008.
  28. Klochkova OA, Kurenkov AL, Namazova-Baranova LS, Mamedyarov AM. Spasticity patterns of hand muscles and botulinum toxin therapy application in patients with cerebral palsy with upper limb involvment. Pediatricheskaya farmakologiya. 2013;10(5):31-39. (In Russ.).
  29. Carraro E, Trevisi E, Martinuzzi A. Safety profile of incobotulinum toxin A [Xeomin®] in gastrocnemious muscles injections in children with cerebral palsy: Randomized double-blind clinical trial. Eur J Paediatr Neurol. 2016;20(4):532-537.  https://doi.org/10.1016/j.ejpn.2016.04.008
  30. Kurenkov AL, Klochkova OA, Bursagova BI, Karimova KM, Kuzenkova LM, Mamedyarov AM, Namazova-Baranova LS, Agranovich OV, Agranovich AO, Soboleva OA, Khapaeva MM, Batysheva TT, Sarzhina MN. Efficacy and safety of botulinum toxin type A (IncobotulinumtoxinA) in the treatment of patients with cerebral palsy. Zh Nevrol Psikhiatr Im SS Korsakova. 2017;117(11):44-51. (In Russ.). https://doi.org/10.17116/jnevro201711711137-44

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.